Sonoda T, Koide T, Oka T, Sakaguchi H, Itatani H, Ohkawa T, Ebisuno S, Morimoto S, Yoshida O, Okada Y
Hinyokika Kiyo. 1985 Nov;31(11):2071-9.
We studied the effect of allopurinol on the prevention of stone recurrence in 134 patients with recurrent, idiopathic calcium nephrolithiasis. They consisted of 113 male patients and 21 female, between 16 and 72 years with an average age of 42.7. The patients were divided into two groups according to the type of stone occurrence; those with multiple stones without previous stone episodes (multiple stone group), and the those with recurrent stones (stone episode group). Twenty three patients belonged to the multiple stone group and 111 patients belonged to the stone episode group. The stones in 19 of the 23 patients in the multiple stone group remained stable throughout the study, while stones in 4 grew. Fifty-nine of the 111 patients in the stone episode group were free from recurrence, but the others showed recurrence. Statistical analyses was done on the stone episode group. The stone recurrence rate of all of the 111 cases showed significant decrease during prophylactic treatment with allopurinol (p less than 0.01), although the observation period before treatment was 73.0 +/- 65.8 months and that during and after treatment was 28.2 +/- 12.1 months. During the two years before and after prophylaxis 79 patients also showed a significantly decreased recurrence rate. Moreover, regarding 37 cases without any stones at the start of treatment, stone recurrence rate decreased significantly after the administration of allopurinol. Throughout this study, we used a new method for evaluating reasonable stone recurrence. It did not calculate the number of stones recurred, but the stone-forming circumstance in each kidney.(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了别嘌呤醇对134例复发性特发性钙肾结石患者预防结石复发的效果。患者包括113名男性和21名女性,年龄在16至72岁之间,平均年龄为42.7岁。根据结石发生类型将患者分为两组:既往无结石发作的多发结石患者(多发结石组)和复发性结石患者(结石发作组)。多发结石组有23例患者,结石发作组有111例患者。多发结石组23例患者中有19例的结石在整个研究过程中保持稳定,而4例患者的结石增大。结石发作组111例患者中有59例无复发,但其他患者出现复发。对结石发作组进行了统计分析。尽管治疗前的观察期为73.0±65.8个月,治疗期间及治疗后的观察期为28.2±12.1个月,但111例患者在接受别嘌呤醇预防性治疗期间结石复发率均显著降低(p小于0.01)。在预防前后的两年中,79例患者的复发率也显著降低。此外,对于治疗开始时无结石的37例患者,服用别嘌呤醇后结石复发率显著降低。在整个研究过程中,我们采用了一种评估合理结石复发的新方法。它不是计算复发结石的数量,而是计算每个肾脏的结石形成情况。(摘要截短于250字)